A citation-based method for searching scientific literature

Christina Alidousty, Nicolai Duerbaum, Svenja Wagener-Ryczek, Till Baar, Luciano G Martelotto, Carina Heydt, Janna Siemanowski, Barbara Holz, Elke Binot, Jana Fassunke, Sabine Merkelbach-Bruse, Jürgen Wolf, Anna Kron, Reinhard Buettner, Anne M Schultheis. Histopathology 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
M Marzec, X Liu, W Wong, Y Yang, T Pasha, K Kantekure, P Zhang, A Woetmann, M Cheng, N Odum,[...]. Oncogene 2011
23
50

Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Jae Seok Lee, Sun Min Lim, Sun Young Rha, Jae Kyung Roh, Yong Jin Cho, Kyu Ho Shin, Woo Ik Yang, Se Hoon Kim, Hyo Song Kim. J Clin Pathol 2014
11
50

Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT).
Hirotaka Nishi, Toshihide Nakada, Satoru Kyo, Masaki Inoue, Jerry W Shay, Keiichi Isaka. Mol Cell Biol 2004
147
50

Ki-67 labeling index in glioblastoma; does it really matter?
Ali Alkhaibary, Ali H Alassiri, Fahd AlSufiani, Mohammed A Alharbi. Hematol Oncol Stem Cell Ther 2019
12
50

Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Sebastian F Schoppmann, Berthold Streubel, Peter Birner. Eur J Cancer 2013
16
50

Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
Emilie Le Rhun, Marc C Chamberlain, Fahed Zairi, Christine Delmaire, Ahmed Idbaih, Florence Renaud, Claude Alain Maurage, Valérie Grégoire. CNS Oncol 2015
9
50

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Kenta Masui, Takashi Komori, Yukinari Kato, Kenkichi Masutomi, Koichi Ichimura, Satoshi Ogasawara, Mika K Kaneko, Hiroharu Oki, Hiroyoshi Suzuki, Masayuki Nitta,[...]. Biomed Res Int 2018
10
50

Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
Federica Del Grosso, Marilena De Mariano, Lorena Passoni, Roberto Luksch, Gian Paolo Tonini, Luca Longo. BMC Cancer 2011
30
50


Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Alexandra Y Tsidulko, Galina M Kazanskaya, Diana V Kostromskaya, Svetlana V Aidagulova, Roman S Kiselev, Alexandr M Volkov, Vyacheslav V Kobozev, Alexei S Gaitan, Alexei L Krivoshapkin, Elvira V Grigorieva. Tumour Biol 2017
17
50

Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment.
George S Stoyanov, Deyan Dzhenkov, Peter Ghenev, Bogomil Iliev, Yavor Enchev, Anton B Tonchev. Med Oncol 2018
28
50

ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation.
Risako Chiba, Masashi Akiya, Miki Hashimura, Yasuko Oguri, Madoka Inukai, Atsuko Hara, Makoto Saegusa. PLoS One 2017
12
50

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients.
Kamila Wojas-Krawczyk, Paweł Adam Krawczyk, Rodryg Adam Ramlau, Justyna Szumiło, Jerzy Kozielski, Ewa Kalinka-Warzocha, Maciej Bryl, Alina Knopik-Dąbrowicz, Lukasz Spychalski, Aleksandra Szczęsna,[...]. Contemp Oncol (Pozn) 2013
4
50

Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome.
George Karagkounis, George Stranjalis, Theodore Argyrakos, Varvara Pantelaion, Konstantinos Mastoris, Dimitra Rontogianni, Spyridon Komaitis, Theodosis Kalamatianos, Damianos Sakas, Dina Tiniakos. J Clin Pathol 2017
7
50

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
50

Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
Mahadev Potharaju, Anugraha Mathavan, Balamurugan Mangaleswaran, Sushama Patil, Reginald John, Siddhartha Ghosh, Chandrasekhar Kalavakonda, Mitra Ghosh, Rama Shanker Verma. J Cancer 2019
7
50

Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.
Ricardo Leão, Joana Dias Apolónio, Donghyun Lee, Arnaldo Figueiredo, Uri Tabori, Pedro Castelo-Branco. J Biomed Sci 2018
81
50

Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: A prospective study in a tertiary care hospital.
Rajdeep Saha, Uttara Chatterjee, Sonali Mandal, Kaushik Saha, Sandip Chatterjee, Samarendra Nath Ghosh. Indian J Med Paediatr Oncol 2014
4
50

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
50

The anaplastic lymphoma kinase in the pathogenesis of cancer.
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. Nat Rev Cancer 2008
568
50

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
U Peretti, R Ferrara, S Pilotto, S Kinspergher, M Caccese, A Santo, M Brunelli, A Caliò, L Carbognin, I Sperduti,[...]. Respir Res 2016
7
50

The Solo Play of TERT Promoter Mutations.
François Hafezi, Danielle Perez Bercoff. Cells 2020
10
50

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.
Federica Zito Marino, Gerardo Botti, Gabriella Aquino, Stefano Ferrero, Gabriella Gaudioso, Alessandro Palleschi, Danilo Rocco, Rosario Salvi, Maria Carolina Micheli, Pietro Micheli,[...]. Int J Mol Sci 2020
3
50

Calcium signaling orchestrates glioblastoma development: Facts and conjunctures.
Catherine Leclerc, Jacques Haeich, Francisco J Aulestia, Marie-Claude Kilhoffer, Andrew L Miller, Isabelle Néant, Sarah E Webb, Etienne Schaeffer, Marie-Pierre Junier, Hervé Chneiweiss,[...]. Biochim Biophys Acta 2016
35
50

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Marta Salido, Lara Pijuan, Luz Martínez-Avilés, Ana B Galván, Israel Cañadas, Ana Rovira, Montserrat Zanui, Alejandro Martínez, Raquel Longarón, Francisco Sole,[...]. J Thorac Oncol 2011
122
50

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
Anne McLeer-Florin, Denis Moro-Sibilot, Adrien Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Elisabeth Brambilla, Sylvie Lantuejoul. J Thorac Oncol 2012
159
50

pROC: an open-source package for R and S+ to analyze and compare ROC curves.
Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Frédérique Lisacek, Jean-Charles Sanchez, Markus Müller. BMC Bioinformatics 2011
50

Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Nicolas Guibert, Anne Pradines, Gilles Favre, Julien Mazieres. Eur Respir Rev 2020
33
50

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Yuxin Cheng, Ting Wang, Xin Lv, Rutian Li, Ling Yuan, Jie Shen, Yan Li, Tingting Yan, Baorui Liu, Lifeng Wang. Cancer Manag Res 2020
9
50

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Alessandra Ferro, Elisabetta Zulato, Ilaria Attili, Giorgia Nardo, Alessandro Dal Maso, Stefano Frega, Andrea Giovanni Menin,[...]. Transl Lung Cancer Res 2021
6
50

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki,[...]. Cancer Res 2019
41
50

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Andreas H Scheel, Gudrun Baenfer, Gustavo Baretton, Manfred Dietel, Rolf Diezko, Thomas Henkel, Lukas C Heukamp, Bharat Jasani, Korinna Jöhrens, Thomas Kirchner,[...]. Histopathology 2018
57
50

Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer.
Jakub Chudziak, Deborah J Burt, Sumitra Mohan, Dominic G Rothwell, Bárbara Mesquita, Jenny Antonello, Suzanne Dalby, Mahmood Ayub, Lynsey Priest, Louise Carter,[...]. Analyst 2016
68
50

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Alexander Haragan, John K Field, Michael P A Davies, Carles Escriu, Aaron Gruver, John R Gosney. Lung Cancer 2019
45
50

Frequent expression of PD-L1 on circulating breast cancer cells.
Martine Mazel, William Jacot, Klaus Pantel, Kai Bartkowiak, Delphine Topart, Laure Cayrefourcq, Delphine Rossille, Thierry Maudelonde, Thierry Fest, Catherine Alix-Panabières. Mol Oncol 2015
212
50

Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Yasuhiro Koh, Satomi Yagi, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi,[...]. Clin Lung Cancer 2019
18
50

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
487
50

Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.
Francesca Fenizia, Raffaella Pasquale, Cristin Roma, Francesca Bergantino, Alessia Iannaccone, Nicola Normanno. Transl Lung Cancer Res 2018
34
50

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies.
Xuan Zhu, Lijie Chen, Ling Liu, Xing Niu. Front Oncol 2019
58
50

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Nicolas Guibert, Myriam Delaunay, Amélie Lusque, Nadia Boubekeur, Isabelle Rouquette, Estelle Clermont, Jean Mourlanette, Sandrine Gouin, Inge Dormoy, Gilles Favre,[...]. Lung Cancer 2018
95
50

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer.
Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Dumenil, Catherine Julie, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie Tisserand, Jean-François Emile, Hélène Blons,[...]. Oncoimmunology 2018
29
50

Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Elena María Brozos-Vázquez, Roberto Díaz-Peña, Jorge García-González, Luis León-Mateos, Patricia Mondelo-Macía, María Peña-Chilet, Rafael López-López. Cancer Immunol Immunother 2021
6
50

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.
Angela Alama, Simona Coco, Carlo Genova, Giovanni Rossi, Vincenzo Fontana, Marco Tagliamento, Maria Giovanna Dal Bello, Alessandra Rosa, Simona Boccardo, Erika Rijavec,[...]. J Clin Med 2019
16
50

Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities.
Zeina Habli, Walid AlChamaa, Raya Saab, Humam Kadara, Massoud L Khraiche. Cancers (Basel) 2020
25
50

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
50

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Nicolas Guibert, Greg Jones, John F Beeler, Vincent Plagnol, Clive Morris, Jean Mourlanette, Myriam Delaunay, Laura Keller, Isabelle Rouquette, Gilles Favre,[...]. Lung Cancer 2019
31
50

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
500
50

Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.
Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Y Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho,[...]. Sci Rep 2021
1
100

Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart. J Thorac Dis 2019
26
50

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Steven J Cohen, Cornelis J A Punt, Nicholas Iannotti, Bruce H Saidman, Kert D Sabbath, Nashat Y Gabrail, Joel Picus, Michael Morse, Edith Mitchell, M Craig Miller,[...]. J Clin Oncol 2008
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.